Interaction of tyrosine kinase inhibitors with the MDR-related ABC transporter proteins

Current Drug Metabolism

Volumn 11, Issue 7, 2010, Pages 618-628

  Wang, Xiao Kun ^a   Fu, Li Wu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ABC transporters; Anticancer drug; Interaction; Multidrug resistance (MDR); Overexpression; Reversal effect; Tyrosine kinase inhibitors (TKIs)

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; ABC TRANSPORTER C1; BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD135 ANTIGEN; CYCLOSPORIN A; DASATINIB; ELACRIDAR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; GLYCOPROTEIN P; IMATINIB; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINCRISTINE; VOTRIENT; ZOSUQUIDAR;

ABDOMINAL PAIN; ACNE; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; DEPIGMENTATION; DIARRHEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRY SKIN; DYSPEPSIA; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAIR DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; MUSCLE CRAMP; MYALGIA; MYELOMONOCYTIC LEUKEMIA; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PLEURA EFFUSION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PRURITUS; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISCOLORATION; TASTE; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 77958110674     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010792927316     Document Type: Review

References (155)

1. Robinson, D. R.; Wu, Y. M.; Lin, S. F. The protein tyrosine kinase family of the human genome. Oncogene, 2000, 19(49), 5548-5557.
2. Arora, A.; Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther., 2005, 315(3), 971-979.
3. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298(5600), 1912-1934.
4. Ozvegy-Laczka, C.; Cserepes, J.; Elkind, N. B.; Sarkadi, B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updat., 2005, 8 (1-2), 15-26.
5. Gschwind, A.; Fischer, O. M.; Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cance, 2004, 4(5), 361-370. (Pubitemid 38579482)
6. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 1996, 2(5), 561-566.
7. Gambacorti-Passerini, C.; le Coutre, P.; Mologni, L.; Fanelli, M.; Bertazzoli, C.; Marchesi, E.; Di Nicola, M.; Biondi, A.; Corneo, G. M.; Belotti, D.; Pogliani, E.; Lydon, N. B. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells, Mol. Dis., 1997, 23(3), 380-394.
8. Lee, S. J.; Wang, J. Y. Exploiting the promiscuity of imatinib. J. Biol., 2009, 8(3), 30.
9. Druker, B. J. Translation of the Philadelphia chromosome into therapy for CML. Blood, 2008, 112(13), 4808-4817.
10. Droogendijk, H. J.; Kluin-Nelemans, H. J.; van Doormaal, J. J.; Oranje, A. P.; van de Loosdrecht, A. A.; van Daele, P. L. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer, 2006, 107(2), 345-351.
11. Distler, J. H.; Distler, O. Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford, England), 2009, 48(1), 2-4.
12. O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Jia, T.; Manley, P. W.; Mestan, J.; Cowan-Jacob, S. W.; Lee, F. Y.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinibresistant Abl kinase domain mutants. Cancer Res., 2005, 65(11), 4500-4505.
13. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305(5682), 399-401.
14. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7(2), 129-141.
15. le Coutre, P.; Ottmann, O. G.; Giles, F.; Kim, D. W.; Cortes, J.; Gattermann, N.; Apperley, J. F.; Larson, R. A.; Abruzzese, E.; O'Brien, S. G.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F. X.; Saglio, G.; Gobbi, M.; Kwong, Y. L.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J. P.; Zheng, M.; Shou, Y.; Kantarjian, H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008, 111(4), 1834-1839.
16. Montemurro, M.; Schoffski, P.; Reichardt, P.; Gelderblom, H.; Schutte, J.; Hartmann, J. T.; von Moos, R.; Seddon, B.; Joensuu, H.; Wendtner, C. M.; Weber, E.; Grunwald, V.; Roth, A.; Leyvraz, S. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur. J. Cancer, 2009, 45(13), 2293-2297.
17. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res., 2006, 66(11), 5790-5797.
18. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med., 2006, 354(24), 2531-2541. (Pubitemid 43882349)
19. Apperley, J. F.; Cortes, J. E.; Kim, D. W.; Roy, L.; Roboz, G. J.; Rosti, G.; Bullorsky, E. O.; Abruzzese, E.; Hochhaus, A.; Heim, D.; de Souza, C. A.; Larson, R. A.; Lipton, J. H.; Khoury, H. J.; Kim, H. J.; Sillaber, C.; Hughes, T. P.; Erben, P.; Van Tornout, J.; Stone, R. M. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J. Clin. Oncol., 2009, 27(21), 3472-3479.
20. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem., 2004, 47(27), 6658-6661.
21. Araujo, J.; Logothetis, C. Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat. Rev., 2010, Available from: http://www.sciencedirect.com/science/article/B6WC8-4YK897K-1/2/ ddb186ce3d3ef352c9c18eee 1594fc7a
22. Kim, L. C.; Rix, U.; Haura, E. B. Dasatinib in solid tumors. Expert Opin. Investig. Drugs., 2010, 19(3), 415-425.
23. Vandyke, K.; Dewar, A. L.; Diamond, P.; Fitter, S.; Schultz, C. G.; Sims, N. A.; Zannettino, A. C. The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through inhibition of osteoclasts in vivo. J. Bone. Miner. Res., 2010, 25(8), 1759-1770.
24. Lee, Y. C.; Huang, C. F.; Murshed, M.; Chu, K.; Araujo, J. C.; Ye, X.; Decrombrugghe, B.; Yu-Lee, L. Y.; Gallick, G. E.; Lin, S. H. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene, 2010, 29(22), 3196-3207
25. O'Farrell, A. M.; Abrams, T. J.; Yuen, H. A.; Ngai, T. J.; Louie, S. G.; Yee, K. W.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 2003, 101(9), 3597-3605.
26. Abrams, T. J.; Lee, L. B.; Murray, L. J.; Pryer, N. K.; Cherrington, J. M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther., 2003, 2(5), 471-478.
27. Chow, L. Q.; Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol., 2007, 25(7), 884-896.
28. Sonpavde, G.; Hutson, T. E. Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. Clin. Genitourin. Cancer, 2008, 6 (Suppl 1), S29-36.
29. Bond, M.; Hoyle, M.; Moxham, T.; Napier, M.; Anderson, R. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer. Health Technol. Assess., 2009, 13 (Suppl 2), 69-74.
30. Demetri, G. D.; van Oosterom, A. T.; Garrett, C. R.; Blackstein, M. E.; Shah, M. H.; Verweij, J.; McArthur, G.; Judson, I. R.; Heinrich, M. C.; Morgan, J. A.; Desai, J.; Fletcher, C. D.; George, S.; Bello, C. L.; Huang, X.; Baum, C. M.; Casali, P. G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368(9544), 1329-1338.
31. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Knight, W. B.; Mullin, R. J.; Gilmer, T. M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther., 2001, 1(2), 85-94.
32. Konecny, G. E.; Pegram, M. D.; Venkatesan, N.; Finn, R.; Yang, G.; Rahmeh, M.; Untch, M.; Rusnak, D. W.; Spehar, G.; Mullin, R. J.; Keith, B. R.; Gilmer, T. M.; Berger, M.; Podratz, K. C.; Slamon, D. J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res., 2006, 66(3), 1630-1639.
33. Geyer, C. E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C. G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S. D.; Stein, S.; Cameron, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med., 2006, 355(26), 2733-2743.
34. Konecny, G. E.; Venkatesan, N.; Yang, G.; Dering, J.; Ginther, C.; Finn, R.; Rahmeh, M.; Fejzo, M. S.; Toft, D.; Jiang, S. W.; Slamon, D. J.; Podratz, K. C. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br. J. Cancer, 2008, 98(6), 1076-1084.
35. Zhou, Y.; Li, S.; Hu, Y. P.; Wang, J.; Hauser, J.; Conway, A. N.; Vinci, M. A.; Humphrey, L.; Zborowska, E.; Willson, J. K.; Brattain, M. G. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res., 2006, 66(1), 404-411.
36. N. L. Spector, K. B., J. Hurley, J. L. Harris, D. Lombardi, S. Bacus, S. B. Ahmed, H. Boussen, M. Frikha and F. B. Ayed EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. J. Clin. Oncol., 2006, 24(18), 502.
37. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64(19), 7099-7109.
38. Auclair, D.; Miller, D.; Yatsula, V.; Pickett, W.; Carter, C.; Chang, Y.; Zhang, X.; Wilkie, D.; Burd, A.; Shi, H.; Rocks, S.; Gedrich, R.; Abriola, L.; Vasavada, H.; Lynch, M.; Dumas, J.; Trail, P. A.; Wilhelm, S. M. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia, 2007, 21(3), 439-445.
39. Guevremont, C.; Jeldres, C.; Perrotte, P.; Karakiewicz, P. I. Sorafenib in the management of metastatic renal cell carcinoma. Curr. Oncol., 2009, 16 (Suppl 1), S27-32.
40. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
41. Song, I. H. Molecular targeting for treatment of advanced hepatocellular carcinoma. Korean J. Hepatol., 2009, 15(3), 299-308.
42. Rahmani, M.; Davis, E. M.; Bauer, C.; Dent, P.; Grant, S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem., 2005, 280(42), 35217-35227.
43. Arteaga, C. L.; Johnson, D. H. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr. Opin. Oncol., 2001, 13(6), 491-498.
44. Rocha-Lima, C. M.; Raez, L. E. Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P. T., 2009, 34(10), 554-564.
45. Cohen, M. H.; Williams, G. A.; Sridhara, R.; Chen, G.; McGuinn, W. D., Jr.; Morse, D.; Abraham, S.; Rahman, A.; Liang, C.; Lostritto, R.; Baird, A.; Pazdur, R. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res., 2004, 10(4), 1212-1218.
46. Vansteenkiste, J. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. Expert Rev. Anticancer Ther., 2004, 4(1), 5-17. (Pubitemid 38208482)
47. Jermann, M.; Stahel, R. A.; Salzberg, M.; Cerny, T.; Joerger, M.; Gillessen, S.; Morant, R.; Egli, F.; Rhyner, K.; Bauer, J. A.; Pless, M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother. Pharmacol., 2006, 57(4), 533-539.
48. Dawson, N. A.; Guo, C.; Zak, R.; Dorsey, B.; Smoot, J.; Wong, J.; Hussain, A. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Cancer Res., 2004, 10(23), 7812-7819.
49. Motzer, R. J.; Hudes, G. R.; Ginsberg, M. S.; Baum, M. S.; Harmon, C. S.; Kim, S. T.; Chen, I.; Redman, B. G. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. Am. J. Clin. Oncol., 2010, (Epub ahead of print).
50. Zhou, S.; Ren, S.; Yan, L.; Zhang, L.; Tang, L.; Zhang, J.; Zhou, C. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology, 2009, 14(5), 709-715.
51. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25(15), 1960-1966.
52. Sternberg, C. N.; Davis, I. D.; Mardiak, J.; Szczylik, C.; Lee, E.; Wagstaff, J.; Barrios, C. H.; Salman, P.; Gladkov, O. A.; Kavina, A.; Zarba, J. J.; Chen, M.; McCann, L.; Pandite, L.; Roychowdhury, D. F.; Hawkins, R. E. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol., 2010, 28(6), 1061-1068.
53. Hutson, T. E.; Davis, I. D.; Machiels, J. P.; De Souza, P. L.; Rottey, S.; Hong, B. F.; Epstein, R. J.; Baker, K. L.; McCann, L.; Crofts, T.; Pandite, L.; Figlin, R. A. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2010, 28(3), 475-480.
54. Sonpavde, G.; Hutson, T. E.; Sternberg, C. N. Pazopanib for the treatment of renal cell carcinoma and other malignancies. Drugs Today (Barc), 2009, 45(9), 651-661.
55. Olaussen, K. A.; Commo, F.; Tailler, M.; Lacroix, L.; Vitale, I.; Raza, S. Q.; Richon, C.; Dessen, P.; Lazar, V.; Soria, J. C.; Kroemer, G. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene, 2009, 28(48), 4249-4260.
56. M. Friedlander, K. C. H., B. Benigno, D. Rischin, M. Messing, C. A. Stringer, E. H. Tay, S. Kathman, G. Matthys and J. J. Lager Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study. J. Clin. Oncol., 2007, 25(18), 5561.
57. Aguilera, D. G.; Tsimberidou, A. M. Dasatinib in chronic myeloid leukemia: a review. Ther. Clin. Risk. Manag., 2009, 5(2), 281-289.
58. Cortes, J.; Kim, D. W.; Raffoux, E.; Martinelli, G.; Ritchie, E.; Roy, L.; Coutre, S.; Corm, S.; Hamerschlak, N.; Tang, J. L.; Hochhaus, A.; Khoury, H. J.; Brummendorf, T. H.; Michallet, M.; Rege-Cambrin, G.; Gambacorti-Passerini, C.; Radich, J. P.; Ernst, T.; Zhu, C.; Van Tornout, J. M.; Talpaz, M. Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Leukemia, 2008, 22(12), 2176-2183.
59. Breccia, M.; Stefanizzi, C.; Cannella, L.; Latagliata, R.; Frustaci, A. M.; Carmosino, I.; Santopietro, M.; Alimena, G. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leuk. Lymphoma., 2008, 49(12), 2328-2332.
60. Dalziel, K.; Round, A.; Stein, K.; Garside, R.; Price, A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol. Assess. (Winchester, England), 2004, 8(28), iii, 1-120.
61. Jabbour, E.; Cortes, J.; Giles, F.; O'Brien, S.; Kantarijan, H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs, 2007, 10(7), 468-479.
62. Chu, T. F.; Rupnick, M. A.; Kerkela, R.; Dallabrida, S. M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Morgan, J. A.; Harris, D. M.; Ismail, N. S.; Chen, J. H.; Schoen, F. J.; Van den Abbeele, A. D.; Demetri, G. D.; Force, T.; Chen, M. H. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007, 370(9604), 2011-2019. (Pubitemid 350236338)
63. Moy, B.; Goss, P. E. Lapatinib: current status and future directions in breast cancer. Oncologist, 2006, 11(10), 1047-1057.
64. Shah, N. P.; Kim, D. W.; Kantarjian, H.; Rousselot, P.; Llacer, P. E.; Enrico, A.; Vela-Ojeda, J.; Silver, R. T.; Khoury, H. J.; Muller, M. C.; Lambert, A.; Matloub, Y.; Hochhaus, A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica, 2010, 95(2), 232-240.
65. Higgins, C. F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol., 1992, 8, 67-113.
66. Vasiliou, V.; Vasiliou, K.; Nebert, D. W. Human ATP-binding cassette (ABC) transporter family. Hum. Genomics, 2009, 3(3), 281-290.
67. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res., 2001, 11(7), 1156-1166. (Pubitemid 32677289)
68. Sharom, F. J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 2008, 9(1), 105-127.
69. Teodori, E.; Dei, S.; Martelli, C.; Scapecchi, S.; Gualtieri, F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets, 2006, 7(7), 893-909.
70. Dean, M.; Annilo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet., 2005, 6, 123-142.
71. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med., 2002, 53, 615-627.
72. Hardwick, L. J.; Velamakanni, S.; van Veen, H. W. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br. J. Pharmacol., 2007, 151(2), 163-174.
73. Robey, R. W.; Polgar, O.; Deeken, J.; To, K. W.; Bates, S. E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis. Rev., 2007, 26(1), 39-57.
74. Stavrovskaya, A. A.; Stromskaya, T. P. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry, 2008, 73(5), 592-604.
75. Kaminski, W. E.; Piehler, A.; Wenzel, J. J. ABC A-subfamily transporters: structure, function and disease. Biochim. Biophys. Acta., 2006, 1762(5), 510-524.
76. Vulevic, B.; Chen, Z.; Boyd, J. T.; Davis, W., Jr.; Walsh, E. S.; Belinsky, M. G.; Tew, K. D. Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res., 2001, 61(8), 3339-3347.
77. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.; Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398.
78. Ho, R. H.; Kim, R. B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther., 2005, 78(3), 260-277.
79. Boonstra, R.; Timmer-Bosscha, H.; van Echten-Arends, J.; van der Kolk, D. M.; van den Berg, A.; de Jong, B.; Tew, K. D.; Poppema, S.; de Vries, E. G. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br. J. Cancer, 2004, 90(12), 2411-2417.
80. Laing, N. M.; Belinsky, M. G.; Kruh, G. D.; Bell, D. W.; Boyd, J. T.; Barone, L.; Testa, J. R.; Tew, K. D. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res., 1998, 58(7), 1332-1337.
81. Gillet, J. P.; Efferth, T.; Steinbach, D.; Hamels, J.; de Longueville, F.; Bertholet, V.; Remacle, J. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res., 2004, 64(24), 8987-8993.
82. Dean, M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia., 2009, 14(1), 3-9.
83. Choudhuri, S.; Klaassen, C. D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol., 2006, 25(4), 231-259.
84. Ernest, S.; Bello-Reuss, E. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. Kidney Int., 1998, 65, S11-17.
85. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev., 2006, 86(4), 1179-1236.
86. Couture, L.; Nash, J. A.; Turgeon, J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol. Rev., 2006, 58(2), 244-258.
87. Kartner, N.; Shales, M.; Riordan, J. R.; Ling, V. Daunorubicinresistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res., 1983, 43(9), 4413-4419.
88. Ueda, K.; Cardarelli, C.; Gottesman, M. M.; Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U. S. A., 1987, 84(9), 3004-3008.
89. Karlsson, J.; Kuo, S. M.; Ziemniak, J.; Artursson, P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol., 1993, 110(3), 1009-1016.
90. Sparreboom, A.; van Asperen, J.; Mayer, U.; Schinkel, A. H.; Smit, J. W.; Meijer, D. K.; Borst, P.; Nooijen, W. J.; Beijnen, J. H.; van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A., 1997, 94(5), 2031-2035.
91. Kim, R. B.; Fromm, M. F.; Wandel, C.; Leake, B.; Wood, A. J.; Roden, D. M.; Wilkinson, G. R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 1998, 101(2), 289-294.
92. Smith, A. J.; van Helvoort, A.; van Meer, G.; Szabo, K.; Welker, E.; Szakacs, G.; Varadi, A.; Sarkadi, B.; Borst, P. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem., 2000, 275(31), 23530-23539.
93. Lecureur, V.; Sun, D.; Hargrove, P.; Schuetz, E. G.; Kim, R. B.; Lan, L. B.; Schuetz, J. D. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol. Pharmacol., 2000, 57(1), 24-35.
94. Stieger, B.; Fattinger, K.; Madon, J.; Kullak-Ublick, G. A.; Meier, P. J. Drug-and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology, 2000, 118(2), 422-430.
95. Cole, S. P.; Sparks, K. E.; Fraser, K.; Loe, D. W.; Grant, C. E.; Wilson, G. M.; Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 1994, 54(22), 5902-5910.
96. Flens, M. J.; Zaman, G. J.; van der Valk, P.; Izquierdo, M. A.; Schroeijers, A. B.; Scheffer, G. L.; van der Groep, P.; de Haas, M.; Meijer, C. J.; Scheper, R. J. Tissue distribution of the multidrug resistance protein. Am. J. Pathol., 1996, 148(4), 1237-1247. (Pubitemid 26111082)
97. Tamai, I.; Yamashita, J.; Kido, Y.; Ohnari, A.; Sai, Y.; Shima, Y.; Naruhashi, K.; Koizumi, S.; Tsuji, A. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J. Pharmacol. Exp. Ther., 2000, 295(1), 146-152.
98. Evers, R.; de Haas, M.; Sparidans, R.; Beijnen, J.; Wielinga, P. R.; Lankelma, J.; Borst, P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer, 2000, 83(3), 375-383.
99. Hooijberg, J. H.; Broxterman, H. J.; Kool, M.; Assaraf, Y. G.; Peters, G. J.; Noordhuis, P.; Scheper, R. J.; Borst, P.; Pinedo, H. M.; Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res., 1999, 59(11), 2532-2535.
100. Huisman, M. T.; Smit, J. W.; Crommentuyn, K. M.; Zelcer, N.; Wiltshire, H. R.; Beijnen, J. H.; Schinkel, A. H. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. (London, England), 2002, 16(17), 2295-2301.
101. Miller, D. S. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J. Pharmacol. Exp. Ther., 2001, 299(2), 567-574.
102. Zeng, H.; Bain, L. J.; Belinsky, M. G.; Kruh, G. D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res., 1999, 59(23), 5964-5967.
103. Zelcer, N.; Saeki, T.; Reid, G.; Beijnen, J. H.; Borst, P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J. Biol. Chem., 2001, 276(49), 46400-46407.
104. St-Pierre, M. V.; Serrano, M. A.; Macias, R. I.; Dubs, U.; Hoechli, M.; Lauper, U.; Meier, P. J.; Marin, J. J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279(4), R1495-1503.
105. Chen, Z. S.; Lee, K.; Walther, S.; Raftogianis, R. B.; Kuwano, M.; Zeng, H.; Kruh, G. D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res., 2002, 62(11), 3144-3150.
106. Lee, K.; Klein-Szanto, A. J.; Kruh, G. D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer. Inst., 2000, 92(23), 1934-1940.
107. Schuetz, J. D.; Connelly, M. C.; Sun, D.; Paibir, S. G.; Flynn, P. M.; Srinivas, R. V.; Kumar, A.; Fridland, A. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med., 1999, 5(9), 1048-1051.
108. Haimeur, A.; Conseil, G.; Deeley, R. G.; Cole, S. P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab., 2004, 5(1), 21-53.
109. Belinsky, M. G.; Kruh, G. D. MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. Br. J. Cancer, 1999, 80(9), 1342-1349.
110. Belinsky, M. G.; Chen, Z. S.; Shchaveleva, I.; Zeng, H.; Kruh, G. D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res., 2002, 62(21), 6172-6177.
111. Kao, H. H.; Huang, J. D.; Chang, M. S. cDNA cloning and genomic organization of the murine MRP7, a new ATP-binding cassette transporter. Gene, 2002, 286(2), 299-306.
112. Hopper-Borge, E.; Chen, Z. S.; Shchaveleva, I.; Belinsky, M. G.; Kruh, G. D. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res., 2004, 64(14), 4927-4930.
113. Bera, T. K.; Lee, S.; Salvatore, G.; Lee, B.; Pastan, I. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol. Med. (Cambridge, Mass), 2001, 7(8), 509-516.
114. Bera, T. K.; Iavarone, C.; Kumar, V.; Lee, S.; Lee, B.; Pastan, I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(10), 6997-7002.
115. Wang, X.; Furukawa, T.; Nitanda, T.; Okamoto, M.; Sugimoto, Y.; Akiyama, S.; Baba, M. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol. Pharmacol., 2003, 63(1), 65-72.
116. Zhao, R.; Raub, T. J.; Sawada, G. A.; Kasper, S. C.; Bacon, J. A.; Bridges, A. S.; Pollack, G. M. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier. Drug Metab. Dispos.: the biological fate of chemicals, 2009, 37(6), 1251-1258.
117. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
118. Kruh, G. D.; Belinsky, M. G. The MRP family of drug efflux pumps. Oncogene, 2003, 22(47), 7537-7552.
119. Gottesman, M. M.; Ling, V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett., 2006, 580(4), 998-1009.
120. Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev., 2006, 86(3), 849-899.
121. Mahon, F. X.; Deininger, M. W.; Schultheis, B.; Chabrol, J.; Reiffers, J.; Goldman, J. M.; Melo, J. V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 2000, 96(3), 1070-1079.
122. Mahon, F. X.; Belloc, F.; Lagarde, V.; Chollet, C.; Moreau-Gaudry, F.; Reiffers, J.; Goldman, J. M.; Melo, J. V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood, 2003, 101(6), 2368-2373.
123. Mahon, F. X.; Hayette, S.; Lagarde, V.; Belloc, F.; Turcq, B.; Nicolini, F.; Belanger, C.; Manley, P. W.; Leroy, C.; Etienne, G.; Roche, S.; Pasquet, J. M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res., 2008, 68(23), 9809-9816.
124. Ozvegy-Laczka, C.; Hegedus, T.; Varady, G.; Ujhelly, O.; Schuetz, J. D.; Varadi, A.; Keri, G.; Orfi, L.; Nemet, K.; Sarkadi, B. Highaffinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol., 2004, 65(6), 1485-1495.
125. Elkind, N. B.; Szentpetery, Z.; Apati, A.; Ozvegy-Laczka, C.; Varady, G.; Ujhelly, O.; Szabo, K.; Homolya, L.; Varadi, A.; Buday, L.; Keri, G.; Nemet, K.; Sarkadi, B. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res., 2005, 65(5), 1770-1777.
126. Yanase, K.; Tsukahara, S.; Asada, S.; Ishikawa, E.; Imai, Y.; Sugimoto, Y. Gefitinib reverses breast cancer resistance proteinmediated drug resistance. Mol. Cancer Ther., 2004, 3(9), 1119-1125.
127. Burger, H.; van Tol, H.; Boersma, A. W.; Brok, M.; Wiemer, E. A.; Stoter, G.; Nooter, K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004, 104(9), 2940-2942.
128. Hegedus, C.; Ozvegy-Laczka, C.; Apati, A.; Magocsi, M.; Nemet, K.; Orfi, L.; Keri, G.; Katona, M.; Takats, Z.; Varadi, A.; Szakacs, G.; Sarkadi, B. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol., 2009, 158(4), 1153-1164.
129. Lagas, J. S.; Vlaming, M. L.; Schinkel, A. H. Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol. Interv., 2009, 9(3), 136-145.
130. Agarwal, S.; Sane, R.; Gallardo, J. L.; Ohlfest, J. R.; Elmquist, W. F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther., 2010, 334(1), 147-155.
131. Oostendorp, R. L.; Buckle, T.; Beijnen, J. H.; van Tellingen, O.; Schellens, J. H. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest. New Drugs, 2009, 27(1), 31-40.
132. Burger, H.; Nooter, K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle (Georgetown, Tex), 2004, 3(12), 1502-1505.
133. Chen, Y.; Agarwal, S.; Shaik, N. M.; Chen, C.; Yang, Z.; Elmquist, W. F.
134. Twentyman, P. R. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol., 1992, 43(1), 109-117.
135. Fischer, V.; Rodriguez-Gascon, A.; Heitz, F.; Tynes, R.; Hauck, C.; Cohen, D.; Vickers, A. E. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos.: the biological fate of chemicals, 1998, 26(8), 802-811.
136. Kruijtzer, C. M.; Beijnen, J. H.; Rosing, H.; ten Bokkel Huinink, W. W.; Schot, M.; Jewell, R. C.; Paul, E. M.; Schellens, J. H. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol., 2002, 20(13), 2943-2950.
137. Houghton, P. J.; Germain, G. S.; Harwood, F. C.; Schuetz, J. D.; Stewart, C. F.; Buchdunger, E.; Traxler, P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res., 2004, 64(7), 2333-2337.
138. Mukai, M.; Che, X. F.; Furukawa, T.; Sumizawa, T.; Aoki, S.; Ren, X. Q.; Haraguchi, M.; Sugimoto, Y.; Kobayashi, M.; Takamatsu, H.; Akiyama, S. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci., 2003, 94(6), 557-563.
139. Hegedus, T.; Orfi, L.; Seprodi, A.; Varadi, A.; Sarkadi, B.; Keri, G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta., 2002, 1587 (2-3), 318-325.
140. Yeheskely-Hayon, D.; Regev, R.; Eytan, G. D.; Dann, E. J. The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line. Leukemia Res., 2005, 29(7), 793-802.
141. Shen, T.; Kuang, Y. H.; Ashby, C. R.; Lei, Y.; Chen, A.; Zhou, Y.; Chen, X.; Tiwari, A. K.; Hopper-Borge, E.; Ouyang, J.; Chen, Z. S. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PloS One, 2009, 4(10), e7520.
142. Kitazaki, T.; Oka, M.; Nakamura, Y.; Tsurutani, J.; Doi, S.; Yasunaga, M.; Takemura, M.; Yabuuchi, H.; Soda, H.; Kohno, S. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer (Amsterdam, Netherlands), 2005, 49(3), 337-343.
143. Nakamura, Y.; Oka, M.; Soda, H.; Shiozawa, K.; Yoshikawa, M.; Itoh, A.; Ikegami, Y.; Tsurutani, J.; Nakatomi, K.; Kitazaki, T.; Doi, S.; Yoshida, H.; Kohno, S. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res., 2005, 65(4), 1541-1546.
144. Zannetti, A.; Iommelli, F.; Fonti, R.; Papaccioli, A.; Sommella, J.; Lettieri, A.; Pirozzi, G.; Bianco, R.; Tortora, G.; Salvatore, M.; Del Vecchio, S. Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. Clin. Cancer Res,, 2008, 14(16), 5209-5219.
145. Shukla, S.; Robey, R. W.; Bates, S. E.; Ambudkar, S. V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab. Dispos.: the biological fate of chemicals, 2009, 37(2), 359-365.
146. Noguchi, K.; Kawahara, H.; Kaji, A.; Katayama, K.; Mitsuhashi, J.; Sugimoto, Y. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci., 2009, 100(9), 1701-1707.
147. Shi, Z.; Peng, X. X.; Kim, I. W.; Shukla, S.; Si, Q. S.; Robey, R. W.; Bates, S. E.; Shen, T.; Ashby, C. R., Jr.; Fu, L. W.; Ambudkar, S. V.; Chen, Z. S. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res., 2007, 67(22), 11012-11020.
148. Dai, C. L.; Tiwari, A. K.; Wu, C. P.; Su, X. D.; Wang, S. R.; Liu, D. G.; Ashby, C. R., Jr.; Huang, Y.; Robey, R. W.; Liang, Y. J.; Chen, L. M.; Shi, C. J.; Ambudkar, S. V.; Chen, Z. S.; Fu, L. W. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res., 2008, 68(19), 7905-7914.
149. Tiwari, A. K.; Sodani, K.; Wang, S. R.; Kuang, Y. H.; Ashby, C. R., Jr.; Chen, X.; Chen, Z. S. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol., 2009, 78(2), 153-161.
150. Kuang, Y. H.; Shen, T.; Chen, X.; Sodani, K.; Hopper-Borge, E.; Tiwari, A. K.; Lee, J. W.; Fu, L. W.; Chen, Z. S. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol., 2010, 79(2), 154-161.
151. Shi, Z.; Parmar, S.; Peng, X. X.; Shen, T.; Robey, R. W.; Bates, S. E.; Fu, L. W.; Shao, Y.; Chen, Y. M.; Zang, F.; Chen, Z. S. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol. Rep., 2009, 21(2), 483-489.
152. Zheng, L. S.; Wang, F.; Li, Y. H.; Zhang, X.; Chen, L. M.; Liang, Y. J.; Dai, C. L.; Yan, Y. Y.; Tao, L. Y.; Mi, Y. J.; Yang, A. K.; To, K. K.; Fu, L. W. Vandetanib (Zactima, ZD6474) antagonizes ABCC1-and ABCG2-mediated multidrug resistance by inhibition of their transport function. PloS One, 2009, 4(4), e5172.
153. Nakanishi, T.; Shiozawa, K.; Hassel, B. A.; Ross, D. D. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood, 2006, 108(2), 678-684.
154. Dohse, M.; Scharenberg, C.; Shukla, S.; Robey, R. W.; Volkmann, T.; Deeken, J. F.; Brendel, C.; Ambudkar, S. V.; Neubauer, A.; Bates, S. E. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab. Dispos.: the biological fate of chemicals, 2010, 38(8), 1371-1380.
155. Burger, H.; van Tol, H.; Brok, M.; Wiemer, E. A.; de Bruijn, E. A.; Guetens, G.; de Boeck, G.; Sparreboom, A.; Verweij, J.; Nooter, K. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol. Ther., 2005, 4(7), 747-752.